The company will separately announce price band and lot size for its IPO in coming few days. The issue will close on August 6.

The price band for the offer could be disclosed separately by the company in coming days. The issue will close on August 6.

Arihant Capital has come out with its report on Rolex Rings. The research firm has recommended to #39;#39;Subscribe#39;#39; the ipo in its research report as on July 27, 2021.

KR Choksey has come out with its report on Rolex Rings. The research firm has recommended to #39;#39;Subscribe#39;#39; the ipo in its research report as on July 28, 2021.

Considering the business growth outlook and almost stable operating margins, Choice Broking assigned a #39;subscribe#39; rating to the issue.

Rolex Rings IPO: At the upper band of IPO price of Rs 900, it is valued at a P/E multiple of 35 (on recalculated EPS excluding the Rs 25 crore deferred tax credit) which is lower than the industry average of 83, said KR Choksey Research.

Rolex Rings IPO: At higher price band of Rs 900, Rolex Rings is demanding a price-to-earnings (P/E) valuation of 28.2x (to its restated FY21 EPS of Rs 31.9) with a market cap of Rs 2,451 crore, while its peers namely Ramkrishna Forgings and MM Forgings are trading at a P/E of 123.30 and 37.14, respectively

Marquee investors participated in the anchor book were Invesco Mutual Fund, Matthews Asia Funds, and HSBC Global Investment Funds.

The public issue will be open for subscription between July 28-30.

Geojit has come out with its report on Glenmark Life Sciences. The research firm has recommended to #39;#39;Subscribe#39;#39; the ipo in its research report as on July 24, 2021.

Ajcon Global has come out with its report on Glenmark Life Sciences. The research firm has recommended to #39;#39;Subscribe#39;#39; the ipo in its research report as on July 26, 2021.

Arihant Capital has come out with its report on Glenmark Life Sciences. The research firm has recommended to #39;#39;Subscribe#39;#39; the ipo in its research report as on July 26, 2021.

Choice Equity Broking has come out with its report on Glenmark Life Sciences. The research firm has recommended to #39;#39;Subscribe#39;#39; the ipo in its research report as on July 23, 2021.

The subsidiary of Glenmark Pharma plans to raise Rs 1,513.6 crore through the public issue which comprises a fresh issue of Rs 1,060 crore, and an offer for sale of 63 lakh equity shares by promoter.

Glenmark Life Sciences IPO: The company has debt-to-equity of 1.3x with a debt of Rs 916 crore which includes Rs 800 crore payable to Glenmark Pharmaceuticals, post-IPO debt will be negligible.